Experimental Ebola vaccine passes 1st hurdle in U.S.

pass it to all

Global News

TORONTO – A single dose of a U.S.-designed Ebola vaccine may be protective against the disease, a new study suggests. But the research also appears to indicate that dose will have to be relatively large, which may present problems for the vaccine.

The study found that people who got the higher of two doses tested in the trial developed immune responses that look similar to those seen in vaccinated non-human primates who survive exposure to what should have been lethal doses of Ebola. Many of them also developed mild to moderate side-effects.

The vaccine was created by scientists at the U.S. National Institute of Allergy and Infectious Diseases and is being developed by Pharma giant GSK, formerly known as GlaxoSmithKline. The study was published online Wednesday by the New England Journal of Medicine.

READ MORE: U.S. looking past Ebola to prepare for next outbreak

Dr. Anthony Fauci, director of the…

View original post 885 more words


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s